Publicacions
El coneixement generat a IrsiCaixa es comparteix amb la comunitat científica a través de la publicació d’articles a revistes científiques d’alt impacte.
VLPs generated by the fusion of RSV-F or hMPV-F glycoprotein to HIV-Gag show improved immunogenicity and neutralizing response in mice.
Nucleic Acid Vaccines Encoding Proteins and Virus-like Particles for HIV Prevention.
Immunization with V987H-stabilized Spike glycoprotein protects K18-hACE2 mice and golden Syrian hamsters upon SARS-CoV-2 infection.
Immunisation efficacy of a stabilised SARS-CoV-2 spike glycoprotein in two geriatric animal models.
A monoclonal antibody targeting a large surface of the receptor binding motif shows pan-neutralizing SARS-CoV-2 activity.
Virus-like particle-mediated delivery of structure-selected neoantigens demonstrates immunogenicity and antitumoral activity in mice.
Safety and immunogenicity of a recombinant protein RBD fusion heterodimer vaccine against SARS-CoV-2.
Exploring FeLV-Gag-Based VLPs as a New Vaccine Platform-Analysis of Production and Immunogenicity.
Cyanovirin-N binds to select SARS-CoV-2 spike oligosaccharides outside of the receptor binding domain and blocks infection by SARS-CoV-2.
Immunogenicity and safety in pigs of PHH-1V, a SARS-CoV-2 RBD fusion heterodimer vaccine candidate.